Researchers at Vanderbilt University Medical Center have relieved symptoms in a mouse model of Rett syndrome with a drug-like compound that works like the dimmer switch in an electrical circuit.
The finding, reported this week in the journal Human Molecular Genetics, suggests a potential new way to treat the rare neurodevelopmental disorder, which occurs predominantly in females, as well as more common forms of autism spectrum disorder.
Further study is needed before this approach can be tested in patients, but animal work from other groups suggests that symptoms in Rett syndrome are reversible, said senior author Colleen Niswender, Ph.D., associate professor of Pharmacology and director of Molecular Pharmacology in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD).
Rett syndrome patients exhibit a constellation of symptoms, including verbal and nonverbal communication deficits, difficulty walking, progressive developmental regression, epilepsy and intellectual disability. The hallmark symptom is repetitive hand movements such as wringing, washing, clapping or tapping.
Most cases of Rett syndrome occur spontaneously from random mutations in the MECP2 gene, which results in disruptions in neurotransmission, including signals mediated by the excitatory transmitter glutamate. A related genetic disorder, termed MECP2 Duplication syndrome, results from overexpression of the MeCP2 protein and is found predominantly in young boys.
The researchers used a mouse model in which MECP2 was “knocked out,” resulting in Rett syndrome-like symptoms. Expression of the metabotropic glutamate receptor 5 (mGlu5), which is important in transmitting nerve signals in the brain, was reduced in brain areas of these mice.
The investigators also found reduced levels of mGlu5 expression in autopsy samples from the brains of Rett syndrome patients, suggesting that the animal work may translate to the clinical population.
They then tested a compound, developed at Vanderbilt, called a positive allosteric modulator or PAM that, like a dimmer switch, “turns up” the activity of mGlu5 when glutamate binds to it.
Animals treated with the compound showed improved motor performance and reduced Rett syndrome-like symptoms, including repetitive clasping of their hind claws.
Previous studies have suggested that enhancing excitatory neurotransmission may increase an already high risk of seizures in Rett patients, but in the current study, seizure occurrence did not increase, even after multiple weeks of chronic dosing with the PAM.
This may be because the compound acts on only a subset of mGlu5-mediated signaling pathways, leaving others unaffected.
“Our work demonstrates that potentiating the activity of mGlu5 can rescue several deficits commonly found in mouse models of Rett syndrome,” said the paper’s first author, Rocco Gogliotti, Ph.D., a postdoctoral fellow in the VCNDD.
“Importantly, by integrating recent advancements in mGlu5 pharmacology into the drug development process, we were able to test the efficacy of our novel compound in a mouse model without observing negative side effects, such as seizures, that have been historically associated with this target,” he said.
Disease progression – and mGlu5 expression – change through time in MeCP2-deficient mice. “A very careful dissection of the time course of the disease is required before modulators of excitatory transmission can be advanced to clinical studies,” Niswender said.
“It may be that early stages of Rett syndrome will need to be treated differently than late-stage disease,” she said.
Learn more: Study reveals possible ‘dimmer switch’ drug for Rett syndrome
The Latest on: Rett syndrome
[google_news title=”” keyword=”Rett syndrome” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
- Rett Syndrome Research Trust selects PMD Solutions…on March 28, 2024 at 8:20 am
STOCKHOLM, SE / ACCESSWIRE / March 28, 2024 / PMD Device Solutions (FRA:8T0)(STO:PMDS) Rett Syndrome Research Trust (RSRT) is proud to announce its partnership with PMD Solutions (PMDS). RSRT's ...
- Rett Syndrome Research Trust selects PMD Solutions' RespiraSense In Their Upcoming US-Based Biosensor Validation Study - VIBRANTon March 28, 2024 at 8:15 am
Rett Syndrome Research Trust (RSRT) is proud to announce its partnership with PMD Solutions (PMDS). RSRT's upcoming US-based biosensor validation study is called ...
- Rett Syndrome: Model of Neurodevelopmental Disorderson March 26, 2024 at 5:00 pm
In the past year, an unusual frequency of gallbladder disease was recognized in girls or women with Rett syndrome (Kathy Hunter, International Rett Syndrome Association, personal communication ...
- Price woman with severe disability who was raped by stepfather dieson March 26, 2024 at 1:18 pm
PRICE, Utah (KUTV) — A Price woman with a severe disability who was raped by her stepfather has died. Ashley Vigil's stepfather, Brian Kenneth Urban, pled guilty to raping her — he's been convicted of ...
- Touching hearts: A Mumbaikar's brave fight against Rett Syndromeon March 23, 2024 at 3:45 am
A Mumbaikar’s brave fight against Rett Syndrome Urgent appeal join the fight to save Mumbaikars life from Rett Syndrome Apollo hospital donate ...
- Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalystson March 20, 2024 at 9:30 am
Taysha Gene Therapies, Inc. has shown further progress in being able to treat patients with Rett Syndrome. Explore more details here.
- Taysha Gene Therapies Shares Jump On Initial Data From First Pediatric Patient With Rare Neurodevelopmental Disorderon March 20, 2024 at 7:23 am
Clinical data from Taysha Gene Therapies on TSHA-102, a potential gene therapy for Rett syndrome. Explore results in improved breathing, motor skills, and seizure management, paving the way for ...
- DepYmed Receives Clearance from U.S. Food and Drug Administration to Initiate Phase 1 Clinical Trial for DPM-1003 for the Treatment of Rett Syndromeon March 19, 2024 at 7:59 am
DepYmed, Inc. (“DepYmed” or the “Company”) is a clinical-stage pharmaceutical company focused on developing transformative medicines for many poorly treated diseases that may benefit significantly by ...
- Rett syndrome: the genetic disorder almost exclusively targeting girlson March 5, 2024 at 4:00 pm
If you haven't heard of Rett syndrome, it's probably because it's very rare. Affecting an estimated one in 12,000 baby girls born each year (and only rarely seen in boys), this genetic disorder ...
- Gene Therapy For a Neurological Disease: Rett Syndromeon February 27, 2024 at 5:45 am
Gene therapy may offer hope for people with a rare childhood disease called Rett syndrome. Around one in 10,000 girls are born each year with Rett syndrome, a rare genetic condition that impacts ...
via Google News and Bing News